Navrogen Announces The Closing Of $3.2M Funding To Support Its Humoral Immuno-Oncology Platform Discovery Technologies And Preclinical Pipeline

Tags:   Preclinical   Immuno-Oncology  

PHILADELPHIA, Sept. 17, 2019 /PRNewswire/ -- Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors.

Previous clinical studies have confirmed that tumors produce immune checkpoint factors that can suppress a patient's immune response to dysregulated cancer cells. The most commonly studied factors have been those that suppress activation of CD8+ T-cells. The therapeutic and commercial success of antagonists against a subset of these checkpoint inhibitors has fueled the industry's interest for developing additional drug candidates that can reverse immuno-suppressive mechanisms against T-cells. Alternatively, humoral immunity, which relies on antibody and complement mediated immune responses against dysregulated cancer cells, has recently been found to be suppressed by tumor-produced proteins, referred to as Humoral Immuno-Oncology (HIO) factors. These factors suppress patient's endogenous humoral responses as well as the pharmacologic effects of antibody-based therapies such as Rituxan® and Herceptin®. Navrogen's mission uniquely focuses on therapeutic solutions to reverse the immuno-suppressive mechanisms mediated by HIO-factors through proprietary screening platforms that identify tumor-derived proteins with HIO-factor activity as well as develop agents that can overcome a HIO-factor's immuno-suppressive effects.

---

---

"Our HIO-factor discovery platforms have enabled us to identify a number of tumor-produced proteins that can suppress a patient's endogenous humoral immune response against cancer cells as well as suppress the therapeutic efficacy of antibody-based drugs," stated Nicholas Nicolaides, Ph.D., Chief Executive Officer at Navrogen.  "Importantly, we have been able to leverage these platforms to develop a pipeline of preclinical agents that can overcome their immuno-suppressive effects and are advancing these agents towards clinical trials."

Luigi Grasso, Ph.D., Chief Scientific Officer of Navrogen added, "It appears that the mechanism of tumor-mediated humoral immuno-suppression is broadly present in a number of cancer types. We are taking on the challenge to develop a new class of anti-cancer therapies for patients whose cancers are associated with elevated HIO-factors and are therefore in need of new medical options"

The use of proceeds, in addition to grant funding, will be used to expand Navrogen's HIO-factor library and support preclinical development activities around its therapeutic pipeline. 

About NavrogenNavrogenTM Inc. is a biotechnology company focused on the discovery of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. Our mission is to develop diagnostic assays that can identify patients whose tumors produce HIO-factors to advise physicians on therapeutic options as well as develop first-in-class agents that can overcome the immuno-suppressive effects of a specific HIO-factor. For more information, please visit www.navrogen.com.

Navrogen Contacts:

Investor Inquiries:              

Media Inquiries:

Nicholas Nicolaides            

Steve Kyriakos

610-660-1931                    

610-660-1927

[email protected]                      

[email protected]

SOURCE Navrogen, Inc.

http://www.navrogen.com

Cision Distribution 888-776-0942 from 8 AM - 9 PM ET